Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?

Annals of hematology - 1 Mar 2013

Banan Mehdi

Abstract excerpt

Hydroxyurea (HU) is a drug that induces fetal hemoglobin production. As a result, HU is widely used to treat β-thalassemia (β-thal) patients. However, the response of these patients to HU varies. Some β-thal patients respond favorably to treatment while others do not respond at all. HU has a numb...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to beta-Thalassemia
Share to Hydroxyurea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Signal Transduction

Share to Treatment Outcome

Source

Identifiers

PMID: 23318979
DOI: 10.1007/s00277-012-1671-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23318979-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?PMID 23318979Read ↗

Successful Use of Hydroxyurea in β-Thalassemia MajorSemantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

Pharmacogenomics and therapeutics of hemoglobinopathies.Semantic proximity Read ↗

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.Semantic proximity Read ↗

Gene polymorphisms predicting response to hydroxyurea treatment in Bahraini patients with sickle cell disease.Semantic proximity Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.